News - Zytiga, Xalkori


Current filters:


Popular Filters

1 to 25 of 48 results

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise


Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

Pfizer’s Xalkori gains regular FDA approval for NSCLC

Pfizer’s Xalkori gains regular FDA approval for NSCLC


The US Food and Drug Administration yesterday (November 21) granted pharma behemoth Pfizer’s Xalkori…

North AmericaOncologyPfizerPharmaceuticalRegulationXalkori

BTG reveals six-month revenue up 17% and meets analysts’ expectations


UK specialist health care company BTG (LSE: BTG) has announced its interim results for the six months…


Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC


Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…


AstraZeneca to co-promote Janssen prostate cancer drug in Japan

AstraZeneca to co-promote Janssen prostate cancer drug in Japan


Anglo-Swedish drug major AstraZeneca has entered into an agreement with US health care giant Johnson…

abirateroneAsia-PacificAstraZenecaJanssenJohnson & JohnsonLicensingMarkets & MarketingOncologyPharmaceuticalZytiga

Prostate cancer market set to grow 50% by 2021: report


The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

NICE says Xalkori is not cost effective in ALK-positive NSCLC


US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…


Six months post launch, US prescribing trends for Xtandi


At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

IQWiG says some men with metastatic prostate cancer can benefit from J&J's Zytiga


In an early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products…

EuropeJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Study shows additional role for abiraterone in blocking tumor growth in CRPC


As part of a European Union-supported IMI-PREDECT consortium (, a Dutch study showed…

abirateroneJanssenJohnson & JohnsonOncologyPharmaceuticalResearchZytiga

Expanded indication for Janssen's Zytiga cleared in EU


US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

New drug options for advanced prostate cancer


Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Prostate cancer drug market will more than double to $9.1 billion in 2021


The prostate cancer drug market will more than double, increasing from $4.1 billion in 2011 to $9.1 billion…

Astellas PharmaGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalXtandiZytiga

Conditional European approval for Pfizer's Xalkori


The European Commission yesterday gave conditional marketing authorization for global drugs behemoth…


ESMO 2012 Congress highlights


The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

1 to 25 of 48 results

Back to top